Hemophagocytic lymphohistiocytosis in adults: Diagnosis and treatment

Joint Bone Spine

Volumn 79, Issue 4, 2012, Pages 356-361

  Larroche, Claire ^a  

^a UNIVERSITÉ PARIS 13   (France)

Author keywords

Hemophagocytic lymphohistiocytosis; Macrophage activation syndrome

Indexed keywords

ALEMTUZUMAB; CYCLOSPORIN; DACLIZUMAB; DEXAMETHASONE; ETOPOSIDE; FERRITIN; FONTOLIZUMAB; IMMUNOGLOBULIN; METHYLPREDNISOLONE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; RITUXIMAB;

BICYTOPENIA; CHOLESTASIS; CLINICAL ASSESSMENT TOOL; CLINICAL FEATURE; CLINICAL PRACTICE; CONGENITAL BLOOD CLOTTING DISORDER; CYTOLYSIS; CYTOTOXICITY; ERYTHROPHAGOCYTOSIS; FERRITIN BLOOD LEVEL; FEVER; GLYCOSYLATION; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HISTOPATHOLOGY; HUMAN; INFLAMMATION; INTERNATIONAL CLASSIFICATION OF DISEASES; JAN INGE HENTER CRITERIA; LABORATORY TEST; LIVER BIOPSY; MACROPHAGE; MACROPHAGE ACTIVATION SYNDROME; MORTALITY; MULTIPLE ORGAN FAILURE; NONHUMAN; ONSET AGE; PANCYTOPENIA; RISK FACTOR; SHORT SURVEY; WEIGHT REDUCTION;

BIOLOGICAL MARKERS; COMBINED MODALITY THERAPY; CYTOPHAGOCYTOSIS; DRUG THERAPY, COMBINATION; ERYTHROCYTES; FERRITINS; HUMANS; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MACROPHAGE ACTIVATION SYNDROME; MACROPHAGES; MULTIPLE ORGAN FAILURE; PROGNOSIS; TERMINOLOGY AS TOPIC;

EID: 84863209652     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2011.10.015     Document Type: Short Survey

References (52)

1. Scott R.B., Robb-Smith A.H.T. Histiocytic medullary reticulosis. Lancet 1939, 234:194-198.
2. Histiocytic medullary reticulosis. Lancet 1983;1:455-6.
3. Risdall R.J., McKenna R.W., Nesbit M.E., et al. Virus-associated hemophagocytic syndrome: a benign histiocytic proliferation distinct from malignant histiocytosis. Cancer 1979, 44:993-1002.
4. Reiner A.P., Spivak J.L. Hematophagic histiocytosis. Medicine 1988, 67:369-388.
5. Stéphan J.L., Zeller J., Hubert P., et al. Macrophage activation syndrome and rheumatic disease in childhood: a report of four new cases. Clin Exp Rheumatol 1993, 11:451-456.
6. Athreya B.H. Is macrophage activation syndrome a new entity?. Clin Exp Rheumatol 2002, 20:121-123.
7. Farquhar J.W., Claireaux A.E. Familial haemophagocytic reticulosis. Arch Dis Child 1952, 27:519-525.
8. Janka G.E. Familial hemophagocytic lymphohistiocytosis. Eur J Pediatr 1983, 140:221-230.
9. Henter J.I., Tondini C., Pritchard J. Histiocyte disorders. Crit Rev Oncol Hematol 2004, 50:157-174.
10. Henter J.I., Elinder G. Haemophagocytic lymphohistiocytosis: an inherited primary form and a reactive secondary form. Br J Haematol 1995, 91:774-775.
11. Favara B.E., Feller A.C., Pauli M., et al. Contemporary classification of histiocytic disorders. The WHO Committee On Histiocytic/Reticulum Cell Proliferations. Reclassification Working Group of the Histiocyte Society. Med Pediatr Oncol 1997, 29:157-166.
12. Henter J.I., Elinder G., Ost A. Diagnostic guidelines for hemophagocytic lymphohistiocytosis. The FHL Study Group of the Histiocyte Society. Semin Oncol 1991, 18:29-33.
13. Pachlopnik Schmid J., Côte M., Ménager M.M., et al. Inherited defects in lymphocyte cytotoxic activity. Immunol Rev 2010, 235:10-23.
14. De Saint Basile G., Ménasché G., Fischer A. Molecular mechanisms of biogenesis and exocytosis of cytotoxic granules. Nat Rev Immunol 2010, 10:568-579.
15. Nagafuji K., Nonami A., Kumano T., et al. Perforin gene mutations in adult-onset hemophagocytic lymphohistiocytosis. Haematologica 2007, 92:978-981.
16. Gholam C., Grigoriadou S., Gilmour K.C., et al. Familial haemophagocytic lymphohistiocytosis: advances in the genetic basis, diagnosis and management. Clin Exp Immunol 2011, 163:271-283.
17. Rohr J., Beutel K., Maul-Pavicic A., et al. Atypical familial hemophagocytic lymphohistiocytosis due to mutations in UNC13D and STXBP2 overlaps with primary immunodeficiency diseases. Haematologica 2010, 95:2080-2087.
18. Meeths M., Entesarian M., Al-Herz W., et al. Spectrum of clinical presentations in familial hemophagocytic lymphohistiocytosis type 5 patients with mutations in STXBP2. Blood 2010, 116:2635-2643.
19. Pachlopnik Schmid J., Canioni D., Moshous D., et al. Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency). Blood 2011, 117:1522-1529.
20. Zhang K., Biroschak J., Glass D.N., et al. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms. Arthritis Rheum 2008, 58:2892-2896.
21. Larroche C., Ziol M., Zidi S., et al. Liver involvement in hemophagocytic syndrome. Gastroenterol Clin Biol 2007, 31:959-966.
22. Janka G.E. Familial and acquired hemophagocytic lymphohistiocytosis. Eur J Pediatr 2007, 166:95-109.
23. Imashuku S. Treatment of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis (EBV-HLH); update 2010. J Pediatr Hematol Oncol 2011, 33:35-39.
24. Esumi N., Ikushima S., Todo S., et al. Hyperferritinemia in malignant histiocytosis and virus-associated hemophagocytic syndrome. N Engl J Med 1987, 316:346-347.
25. Allen C.E., Yu X., Kozinetz C.A., et al. Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2008, 50:1227-1235.
26. Francois B., Trimoreau F., Vignon P., et al. Thrombocytopenia in the sepsis syndrome: role of hemophagocytosis and macrophage colony-stimulating factor. Am J Med 1997, 103:114-120.
27. Lambotte O., Cacoub P., Costedoat N., et al. High ferritin and low glycosylated ferritin may also be a marker of excessive macrophage activation. J Rheumatol 2003, 30:1027-1028.
28. Fardet L., Coppo P., Kettaneh A., et al. Low glycosylated ferritin, a good marker for the diagnosis of hemophagocytic syndrome. Arthritis Rheum 2008, 58:1521-1527.
29. Wang Z., Wang Y., Wang J., et al. Early diagnostic value of low percentage of glycosylated ferritin in secondary hemophagocytic lymphohistiocytosis. Int J Hematol 2009, 90:501-505.
30. Hot A., Toh M.L., Coppéré B., et al. Reactive hemophagocytic syndrome in adult-onset Still disease: clinical features and long-term outcome: a case-control study of 8 patients. Medicine 2010, 89:37-46.
31. Takahashi N., Chubachi A., Kume M., et al. A clinical analysis of 52 adult patients with hemophagocytic syndrome: the prognostic significance of the underlying diseases. Int J Hematol 2001, 74:209-213.
32. Kaito K., Kobayashi M., Katayama T., et al. Prognostic factors of hemophagocytic syndrome in adults: analysis of 34 cases. Eur J Haematol 1997, 59:247-253.
33. Lin T.F., Ferlic-Stark L.L., Allen C.E., et al. Rate of decline of ferritin in patients with hemophagocytic lymphohistiocytosis as a prognostic variable for mortality. Pediatr Blood Cancer 2011, 56:154-155.
34. Henter J.I., Horne A., Arico M., et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007, 48:124-131.
35. Buyse S., Teixeira L., Galicier L., et al. Critical care management of patients with hemophagocytic lymphohistiocytosis. Intensive Care Med 2010, 36:1695-1702.
36. Chibane S., Feldman-Billard S., Rossignol I., et al. Short-term tolerance of three days pulse methyprednisolone therapy: a prospective study in 146 patients. Rev Med Interne 2005, 26:20-26.
37. Ambruso D.R., Hays T., Zwartjes W.J., et al. Successful treatment of lymphohistiocytic reticulosis with phagocytosis with epipodophyllotoxin VP 16-213. Cancer 1980, 45:2516-2520.
38. Stebbing J., Ngan S., Ibrahim H., et al. The successful treatment of haemophagocytic syndrome in patients with human immunodeficiency virus-associated multi-centric Castleman's disease. Clin Exp Immunol 2008, 154:399-405.
39. Imashuku S. Etoposide-related secondary acute myeloid leukemia (t-AML) in hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007, 48:121-123.
40. Tsuda H., Shirono K. Successful treatment of virus-associated haemophagocytic syndrome in adults by cyclosporin A supported by granulocyte colony-stimulating factor. Br J Haematol 1996, 93:572-575.
41. Ravelli A., Viola S., De Benedetti F., et al. Dramatic efficacy of cyclosporine A in macrophage activation syndrome. Clin Exp Rheumatol 2001, 19:108.
42. Yakushijin K., Mizuno I., Sada A., et al. Cyclosporin neurotoxicity with Epstein-Barr virus-associated hemophagocytic syndrome. Haematologica 2005, 90:ECR11.
43. Larroche C., Bruneel F., Andre M.H., et al. Comité d'évaluation et de diffusion des innovation technologiques (CEDIT). Intravenously administered gamma-globulins in reactive hemaphagocytic syndrome. Multicenter study to assess their importance, by the immunoglobulins group of experts of CEDIT of the AP-HP. Ann Med Interne (Paris) 2000, 151:533-539.
44. Emmenegger U., Frey U., Reimers A., et al. Hyperferritinemia as indicator for intravenous immunoglobulin treatment in reactive macrophage activation syndromes. Am J Hematol 2001, 68:4-10.
45. Jordan M.B., Hildeman D., Kappler J., et al. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood 2004, 104:735-743.
46. Reinisch W., de Villiers W., Bene L., et al. Fontolizumab in moderate to severe Crohn's disease: a phase II, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm Bowel Dis 2010, 16:233-242.
47. Sandhu C., Chesney A., Piliotis E., et al. Macrophage activation syndrome after etanercept treatment. J Rheumatol 2007, 34:241-242.
48. Nigrovic P.A., Mannion M., Prince F.H., et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 2011, 63:545-555.
49. Ménard F., Besson C., Rincé P., et al. Hodgkin lymphoma-associated hemophagocytic syndrome: a disorder strongly correlated with Epstein-Barr virus. Clin Infect Dis 2008, 47:531-534.
50. Kamiya K., Kurasawa K., Arai S., et al. Rituximab was effective on refractory thrombotic thrombocytopenic purpura but induced a flare of hemophagocytic syndrome in a patient with systemic lupus erythematosus. Mod Rheumatol 2010, 20:81-85.
51. Olin R.L., Nichols K.E., Naghashpour M., et al. Successful use of the anti-CD25 antibody daclizumab in an adult patient with hemophagocytic lymphohistiocytosis. Am J Hematol 2008, 83:747-749.
52. Strout M.P., Seropian S., Berliner N. Alemtuzumab as a bridge to allogeneic SCT in atypical hemophagocytic lymphohistiocytosis. Nat Rev Clin Oncol 2010, 7:415-420.